Lumibird
LBIRD.PA Small CapHealthcare · Diagnostics & Research
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, time-of-flight LiDAR and rangefinders, military laser rangefinders, and medical and ophthalmological solutions. The company serves defense and space, environment, topography and safety, industry and science, and science and healthcare industries. Lumibird SA was incorporated in 1970 and is headquartered in Lannion, France. Lumibird SA is a subsidiary of ESIRA.
Lumibird Stock at a Glance
Lumibird (LBIRD.PA) is currently trading at €26.90 with a market capitalization of $593.6M. The trailing P/E ratio stands at 42.03x, with a forward P/E of 22.99x. The 52-week range spans from €15.75 to €27.65; the current price is 2.7% below the yearly high. Year-over-year revenue growth stands at +8.5%. The net profit margin stands at 6.13%.
💰 Dividend
Lumibird pays an annual dividend of €0.37 per share, representing a yield of 1.38%.
📊 Analyst Rating
3 analysts rate Lumibird (LBIRD.PA) on consensus: None. The average price target is €29.50, implying +9.67% from the current price. Analyst price targets range from €28.50 to €30.00.
Lumibird: The Investment Case in Detail
Lumibird (LBIRD.PA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Earnings growth of 58.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 63.36%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
The Bear Case
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
What to Watch Next
- The forward P/E of 22.99x is meaningfully below the trailing 42.03x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 93.7% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 63.36% — indicates pricing power
- Positive free cash flow
- –Currently flagged as overvalued
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Lumibird (LBIRD.PA) 2026: 23,50 EUR French Laser-and-Photonics Specialist with Scientific-Industrial-and-Medical Diversification and 1,57 Percent Dividend Yield
The Real Story
Lumibird SA (Euronext Paris: LBIRD) is a Lannion, France-headquartered laser-and-photonics-specialist designing, manufacturing, and selling various lasers for scientific, industrial, and medical applications. Three segments: Medical (ophthalmology lasers, lithotripsy), Photonics (industrial-laser-systems for marking, welding, materials-processing), and Scientific (research-grade lasers for academic-and-defense applications).
Formed 2017 from merger of Quantel and Keopsys plus subsequent acquisitions (Ellex Medical 2020). Forward-P/E 20,1x reflects expected margin-recovery.
What Smart Money Thinks
Lumibird has French-institutional base. ESIRA SAS (CEO Marc Le Flohic family-affiliated) holds approximately 20 percent. Bpifrance at approximately 8,2 percent — French sovereign-investment. Crédit Mutuel Asset Management at approximately 4,8 percent. Short-interest sits at approximately 2 percent of float as of May 2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Medical-laser segment (~40 percent of revenue) provides defensive recurring base for ophthalmology procedures (cataract, refractive, retinal). Less correlated to industrial-cycle volatility.
Industrial-laser demand grows approximately 8-12 percent annually from EV-battery-welding, additive-manufacturing, semiconductor-packaging applications.
CEO Marc Le Flohic and Bpifrance combined 28+ percent control provides long-duration discipline through cycle.
📉 The 3 Real Bear Points
European industrial-capex weakness compresses photonics-segment revenue trajectory.
Larger laser-and-photonics competitors compress Lumibird pricing-power on industrial applications.
Forward-P/E 20x reflects expected margin-recovery. Recovery-slip would compress multiple.
Valuation in Context
Lumibird at 23,50 EUR per share with approximately 22 million shares outstanding has a market capitalization of approximately 519 million EUR. Forward-P/E 20,1x.
Re-rating to 16-19x on consensus fiscal-2027 EPS 1,40 EUR supports 22-27 EUR — modest upside. Bear-case 14-17 EUR. Bull-case 32-38 EUR over 24-36 months.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
H1 2026 earnings. Watch-items: medical-segment growth, industrial-laser cycle, margin-recovery.
-
2027 Q1:
Fiscal-2026 full-year results plus fiscal-2027 guidance.
-
2027 H2:
Continued industrial-cycle progression.
💬 Daniel's Take
Lumibird is a quality-cyclical French laser-and-photonics specialist with defensive ophthalmology base, industrial-photonics growth tailwind, Le Flohic-CEO and Bpifrance anchor. Position-sizing: 0,3–0,8 percent.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Lumibird?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news